Literature DB >> 11756177

ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.

Emma Camacho1, Luis Hernández, Silvia Hernández, Frederic Tort, Beatriz Bellosillo, Silvia Beà, Francesc Bosch, Emili Montserrat, Antonio Cardesa, Pedro L Fernández, Elias Campo.   

Abstract

The ataxia-telangiectasia mutated (ATM) gene codifies for a protein critically involved in the cellular response to DNA damage. ATM alterations have been observed in some sporadic lymphoproliferative disorders. The recurrent 11q22-23 deletions found in mantle cell lymphoma (MCL) suggest that ATM could be inactivated in these lymphomas. In this study, ATM gene alterations and protein expression were examined in 20 and 17 MCL tumor specimens, respectively. Previously, these patients had been examined for p53 and p14(ARF) gene status and analyzed by comparative genomic hybridization. Nine patients had 11q22-23 losses. Eight ATM gene mutations were detected in 7 patients. These alterations were 3 missense mutations in the phosphatidylinositol-3 kinase (PI-3K) domain and 5 truncating mutations, including 3 frameshifts, a nonsense mutation, and a substitution of the initial methionine. All truncating mutations were associated with lack of protein expression. Somatic origin was demonstrated in 3 mutations, whereas one mutation was carried heterozygously in the patient germ line. Chromosomal imbalances were significantly higher in typical MCL with ATM inactivation (7.8 +/- 1.3) than in tumors with the wild-type gene (3 +/- 1.1) (P =.001). Moreover, tumors with bi-allelic ATM alteration were associated with 3q gains (P =.015) and frequent extranodal involvement (P =.049). ATM gene alterations were not related to the histologic variant of the tumors, p53/p14(ARF) gene status, survival, or other clinicopathologic features of the patients. These findings indicate that ATM gene mutations in MCL are mainly truncating or missense mutations involving the PI-3K domain, and that may play a role in the pathogenesis of a subset of these tumors with increased numbers of chromosomal imbalances.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11756177     DOI: 10.1182/blood.v99.1.238

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

Review 1.  Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

Authors:  Patricia Pérez-Galán; Martin Dreyling; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

Review 2.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

3.  A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma.

Authors:  Ryan D Cassaday; Andre Goy; Suresh Advani; Purvi Chawla; Rajesh Nachankar; Mansi Gandhi; Ajay K Gopal
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2015-03-05

Review 4.  Cancer Clonal Theory, Immune Escape, and Their Evolving Roles in Cancer Multi-Agent Therapeutics.

Authors:  Jonathan L Messerschmidt; Prianka Bhattacharya; Gerald L Messerschmidt
Journal:  Curr Oncol Rep       Date:  2017-08-12       Impact factor: 5.075

5.  Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research.

Authors:  Magdalena Klanova; Tomas Soukup; Radek Jaksa; Jan Molinsky; Lucie Lateckova; Bokang C L Maswabi; Dana Prukova; Jana Brezinova; Kyra Michalova; Petra Vockova; Francisco Hernandez-Ilizaliturri; Vojtech Kulvait; Jan Zivny; Martin Vokurka; Emanuel Necas; Marek Trneny; Pavel Klener
Journal:  Lab Invest       Date:  2014-05-26       Impact factor: 5.662

Review 6.  Molecular pathogenesis of mantle cell lymphoma.

Authors:  Pedro Jares; Dolors Colomer; Elias Campo
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

7.  Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.

Authors:  Kenneth L Pitter; Dana L Casey; Yue C Lu; Margaret Hannum; Zhigang Zhang; Xinmao Song; Isabella Pecorari; Biko McMillan; Jennifer Ma; Robert M Samstein; Isaac X Pei; Atif J Khan; Lior Z Braunstein; Luc G T Morris; Christopher A Barker; Andreas Rimner; Kaled M Alektiar; Paul B Romesser; Christopher H Crane; Joachim Yahalom; Michael J Zelefsky; Howard I Scher; Jonine L Bernstein; Diana L Mandelker; Britta Weigelt; Jorge S Reis-Filho; Nancy Y Lee; Simon N Powell; Timothy A Chan; Nadeem Riaz; Jeremy Setton
Journal:  J Natl Cancer Inst       Date:  2021-03-01       Impact factor: 13.506

Review 8.  Molecular Pathogenesis of Mantle Cell Lymphoma.

Authors:  Alba Navarro; Sílvia Beà; Pedro Jares; Elías Campo
Journal:  Hematol Oncol Clin North Am       Date:  2020-07-22       Impact factor: 3.722

Review 9.  Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy.

Authors:  Kevin Wang; Xiangao Huang; Maurizio Di Liberto; Selina Chen-Kiang
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-01       Impact factor: 3.722

10.  Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias.

Authors:  Jane Starczynski; William Simmons; Joanne R Flavell; Phillip J Byrd; Grant S Stewart; Harjit S Kullar; Alix Groom; John Crocker; Paul A H Moss; Gary M Reynolds; Meri Glavina-Durdov; A Malcolm R Taylor; Christopher Fegan; Tatjana Stankovic; Paul G Murray
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.